PFIZER INC, LEO PHARMA A/S and BIOFRONTERA AG are Dominating the U.S Rx Dermatology Topical Drug Delivery Market in 2019

Rx Dermatology Topical Drug Delivery Market is expected to grow with the CAGR of 4.9% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/us-rx-dermatology-topical-drug-delivery-market

Rx dermatology topical drug delivery market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Rx dermatology topical drug delivery market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio. For instance, in December 2019, GlaxoSmithKline plc acquired TESARO Inc (U.S.) for an amount of approximately USD 5.1 billion. By this acquisition company provide strengthen to oncology business.

PFIZER INC is the dominating player in Rx dermatology topical drug delivery market. The other key players existing in the market includes Leo Pharma A/S, BIOFRONTERA AG, Glaxosmithkline plc, Allergan, Almirall, S.A, Galderma Laboratories, L.P, Mayne Pharma Group Limited, Novartis AG and Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Pfizer Inc, headquartered in New York, U.S. which was founded in 1849. The main focus of the company is to develop and distribute medicines in therapeutic areas of all diseases and their business segments are Innovative Health (IH), Essential Health (EH). The company offer its product in different categories such as prescription and over the counter whereas Innovative Health (IH), Essential Health (EH) lies under business segments of the company. In December 31st 2018 the company registered 92,400 employees.

The company has wide global presence across the globe such as Europe, Middle East & Africa, Asia-Pacific, South America, and North America. In addition to it, the company also generates its revenue from the various subsidiary companies such as Agouron Pharmaceuticals, LLC (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC (U.S.) and G. D. Searle & Co. Limited (U.K.) among others among others.

For instance,

• In May 2016, Pfizer Inc. acquired Anacor Pharmaceuticals Inc ANAC.O with the huge amount of about USD 5.2 billion. The aim behind this acquisition was to increase their product portfolio with the addition of eczema gel to its portfolio. The acquisition gave an opportunity to Pfizer Inc. for addressing a significant unmet medical need for a large patient population.

 LEO Pharma A/S

LEO Pharma A/S is headquartered in Ballerup, Denmark and it was founded in year 1908. The company is engaged in becoming the preferred dermatology care partner by improving people’s lives around the world by expanding their business in new regions and markets to address unmet medical needs. The company offer its product under two categories dermatology, and thrombosis. The total number of employees of the company is 5,528.The company has presence in Asia, Europe, Middle East & Africa, South America, and North America.

For instance,

• In April 2019, LEO Pharma A/S announced the partnership with Elektrofi (U.S.) to achieve improvements in drug delivery within dermatology. The aim behind this partnership was to provide new, more convenient solutions for drug delivery in market for the patients.

BIOFRONTERA AG 

BIOFRONTERA AG is headquartered in Massachusetts, U.S. was founded in 1997. The company offer product in the categories of Ameluz, BF-Rhodoled and Belixos. The company focuses on the development and commercialization of the dermatological and cosmetics medicines with special focus on the photodynamic therapy for skin diseases with intensive knowledge regarding the therapy. Its subsidiaries are Biofrontera Bioscience GmbH (Germany), Biofrontera Pharma GmbH (Germany), Biofrontera Development GmbH (Germany), Biofrontera Neuroscience GmbH (Germany) and Biofrontera Inc. (Germany) among others. The company has wide global presence in Germany, Europe and the U.S.

For instance, In January, Biofrontera AG has received U.S. Food and Drug Administration (FDA) for upscaling the batch production of Ameluz to 35 kg from 7 kg in past years. Biofrontera AG has also got approval from the European Medicines Agency (EMA). This fivefold increase in the production of Ameluz benefits Biofrontera AG to meet the growing requirement for Ameluz worldwide.